We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
+7.66%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$1.06B
AUM Growth
+$390M
Cap. Flow
+$371M
Cap. Flow %
35.1%
Top 10 Hldgs %
89.14%
Holding
24
New
5
Increased
–
Reduced
6
Closed
–

Top Buys

Rank Stock Value
1
NUVB icon
Nuvation Bio
NUVB
+$315M
2
IMA
ImageneBio Inc
IMA
+$64.2M
3
SANA icon
Sana Biotechnology
SANA
+$27.5M
4
OMEG
Omega Alpha SPAC Class A Ordinary Shares
OMEG
+$5.2M
5
IMCR icon
Immunocore
IMCR
+$2.29M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$29.8M
2
EPIX
ESSA Pharma
EPIX
+$8.57M
3
REPL icon
Replimune Group
REPL
+$2.49M
4
PVLA
Palvella Therapeutics
PVLA
+$1.43M
5
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$651K

Sector Composition

Rank Sector Weight
1 Healthcare 99.53%
2 Financials 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB icon
1
Nuvation Bio
NUVB
$2.24B
$295M 27.89%
+28,212,376
New +$315M
REPL icon
2
Replimune Group
REPL
$814M
$153M 14.45%
5,008,245
-66,538
-1% -$2.49M
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$144M 13.6%
2,272,478
-649,293
-22% -$29.8M
KRON
4
DELISTED
Kronos Bio
KRON
$112M 10.57%
3,818,283
– –
IMA
5
ImageneBio Inc
IMA
$63.1M
$63.5M 6.01%
+187,427
New +$64.2M
AVIR icon
6
Atea Pharmaceuticals
AVIR
$379M
$52.3M 4.95%
847,208
– –
SPRB
7
Spruce Biosciences
SPRB
$119M
$35.9M 3.39%
28,814
– –
GOSS icon
8
Gossamer Bio
GOSS
$66.5M
$30.7M 2.91%
3,320,608
– –
IMUX icon
9
Immunic
IMUX
$182M
$28.5M 2.7%
178,816
– –
SANA icon
10
Sana Biotechnology
SANA
$885M
$28.2M 2.67%
+843,750
New +$27.5M
PRTK
11
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$18.4M 1.74%
2,600,410
– –
ARQT icon
12
Arcutis Biotherapeutics
ARQT
$3.42B
$18M 1.71%
623,836
-16,363
-3% -$511K
CMPI
13
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$16.2M 1.53%
1,335,050
– –
ALPN
14
DELISTED
Alpine Immune Sciences Inc
ALPN
$13.6M 1.29%
1,284,900
– –
SYRS
15
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$11.7M 1.11%
156,250
– –
EPIX
16
DELISTED
ESSA Pharma
EPIX
$9.79M 0.93%
336,869
-368,824
-52% -$8.57M
CDTX
17
DELISTED
Cidara Therapeutics
CDTX
$5.33M 0.5%
100,262
– –
OMEG
18
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$5M 0.47%
+501,000
New +$5.2M
KYNB
19
Kyntra Bio
KYNB
$28.5M
$4.54M 0.43%
5,226
– –
TRVI icon
20
Trevi Therapeutics
TRVI
$2.49B
$3.42M 0.32%
1,263,408
– –
OBSV
21
DELISTED
ObsEva SA Ordinary Shares
OBSV
$3.25M 0.31%
999,364
– –
JNCE
22
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.83M 0.27%
275,513
-59,452
-18% -$651K
IMCR icon
23
Immunocore
IMCR
$1.78B
$2.19M 0.21%
+51,535
New +$2.29M
PVLA
24
Palvella Therapeutics
PVLA
$1.98B
$580K 0.05%
2,822
-6,562
-70% -$1.43M

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q1 2021 Portfolio in Review

As of Q1 2021, Omega Fund Management held 24 positions worth $1.06B, up 59% from $667M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Omega Fund Management deployed $371M of net new capital in Q1 2021, opening 5 new positions. Its largest new stake was Nuvation Bio: 28,212,376 shares worth $295M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Morphic Holding, Inc. Common Stock, an estimated $29.8M trimmed.

  • Omega Fund Management's largest Q1 2021 buy was Nuvation Bio: 28,212,376 shares worth $295M.
  • Omega Fund Management's biggest Q1 2021 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $29.8M.
  • Omega Fund Management's ten largest holdings make up 89% of its $1.06B portfolio in Q1 2021.
  • Omega Fund Management opened 5 new positions and closed 0 in Q1 2021.
  • Omega Fund Management's portfolio value rose 59% quarter-over-quarter to $1.06B.

Based on Omega Fund Management's 13F filing for Q1 2021, filed 17 May 2021.